Show simple item record

dc.contributor.authorMüller, Laura
dc.contributor.authorMurgia, Xabier
dc.contributor.authorSiebenbürger, Lorenz
dc.contributor.authorBörger, Carsten
dc.contributor.authorSchwarzkopf, Konrad
dc.contributor.authorSewald, Katherina
dc.contributor.authorHäussler, Susanne
dc.contributor.authorBraun, Armin
dc.contributor.authorLehr, Claus-Michael
dc.contributor.authorHittinger, Marius
dc.contributor.authorWronski, Sabine
dc.date.accessioned2020-09-09T09:12:03Z
dc.date.available2020-09-09T09:12:03Z
dc.identifier.citationJ Antimicrob Chemother. 2018;73(10):2762-2769. doi:10.1093/jac/dky241.en_US
dc.identifier.pmid29982453
dc.identifier.doi10.1093/jac/dky241
dc.identifier.urihttp://hdl.handle.net/10033/622430
dc.description.abstractObjectives: In the context of cystic fibrosis, Pseudomonas aeruginosa biofilms often develop in the vicinity of airway mucus, which acts as a protective physical barrier to inhaled matter. However, mucus can also adsorb small drug molecules administered as aerosols, including antibiotics, thereby reducing their bioavailability. The efficacy of antibiotics is typically assessed by determining the MIC using in vitro assays. This widespread technique, however, does not consider either bacterial biofilm formation or the influence of mucus, both of which may act as diffusion barriers, potentially limiting antibiotic efficacy. Methods: We grew P. aeruginosa biofilms in the presence or absence of human tracheal mucus and tested their susceptibility to tobramycin and colistin. Results: A significant reduction of tobramycin efficacy was observed when P. aeruginosa biofilms were grown in the presence of mucus compared with those grown in the absence of mucus. Diffusion of tobramycin through mucus was reduced; however, this reduction was more pronounced in biofilm/mucus mixtures, suggesting that biofilms in the presence of mucus respond differently to antibiotic treatment. In contrast, the influence of mucus on colistin efficacy was almost negligible and no differences in mucus permeability were observed. Conclusions: These findings underline the important role of mucus in the efficacy of anti-infective drugs.en_US
dc.language.isoenen_US
dc.publisherOxford Academicen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleHuman airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.eissn1460-2091
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalThe Journal of antimicrobial chemotherapyen_US
dc.source.volume73
dc.source.issue10
dc.source.beginpage2762
dc.source.endpage2769
refterms.dateFOA2020-09-09T09:12:03Z
dc.source.journaltitleThe Journal of antimicrobial chemotherapy
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Müller et al.pdf
Size:
541.6Kb
Format:
PDF
Description:
delayed Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International